Published on in Vol 7, No 7 (2018): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11191, first published .
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Journals

  1. Peter M, Bilenky M, Isserlin R, Bader G, Shen S, De Carvalho D, Hansen A, Hu P, Fleshner N, Joshua A, Hirst M, Bapat B. Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. Epigenomics 2020;12(15):1317 View
  2. Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabrò F, Tema G, Leonardo C, Flammia R, Tuderti G, Anceschi U, Brassetti A, Giacinti S, Guaglianone S, Ghahhari J, Schips L, Tubaro A, Gallucci M, Simone G. Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World Journal of Urology 2020;38(7):1757 View
  3. Cardoso P, Santos C, Costa F, Rocha-Gonçalves F. Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Global Journal on Quality and Safety in Healthcare 2020;3(2):65 View
  4. Scailteux L, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E. Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014–2018 French Population Study (the SPEAR Cohort). American Journal of Epidemiology 2021;190(3):413 View
  5. Lin Y, Huang Y, Liu C, Lee T, Chen M, Chien Y. Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide. Frontiers in Pharmacology 2021;12 View